Impact of Adipose Tissue in COVID-19

NCT04639440 | Unknown

• 2 other identifiers: APHP2009832020-A02403-36
• Study Type: observational
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

Overweight or obese patients are particularly exposed to severe forms of COVID-19. Few data suggest that adipose tissue infected with SARS-CoV-2 could be involved in the onset of the cytokine storm seen in severe forms of COVID-19. The aim of this study is to determine the pathogenesis of SARS-CoV-2-infection of adipose tissue. In particular the investigators will study how this virus enters the adipocyte and how it modulates metabolism and inflammation in the adipose tissue. From these data, the investigators hope to determine at the adipose tissue level, original therapeutic targets to modulate the effects of SARS-CoV-2 at the systemic level.

Conditions

Covid19

Keywords

Adipose tissue; Covid19; SARS-CoV2

Outcome Measures

Primary Outcomes (1)

• Comparison of the expression of ACE2 and TMPRSS2 in the subcutaneous and visceral adipose tissue of obese patients. Determination of cells expressing ACE2 and TMPRSS2 in whole human adipose tissue.

  Analysis of the expression of mRNA and ACE2 and TMPRSS2 proteins in the subcutaneous and visceral adipose tissue of normal weight and obese patients

  12 months

Secondary Outcomes (5)

• Demonstration of entry and replication of SARS-CoV-2 in human adipose tissue

  12 months

• Consequences of infection with SARS-CoV-2 on the metabolism and inflammatory state of adipose tissue.

  12 months

• Consequences of infection with SARS-CoV-2 on the metabolism and inflammatory state of adipose tissue.

  12 months

• Effect of SARS-CoV-2 infection of adipose tissue / adipocytes from thin and obese subjects on endoplasmic reticulum (ER) homeostasis.

  12 months

• Target endoplasmic reticulum stress to reduce spread of SARS-CoV-2 from adipose tissue

  12 months

Study Arms (2)

Obese or overweight patients

Other: Adipose tissue

Patients without overweight

Other: Adipose tissue

Interventions

Adipose tissue OTHER

Adipose tissue sampling

Obese or overweight patients; Patients without overweight

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Obese and thin patients operated on for abdominal vascular surgery.

You may qualify if:

• Age greater than or equal to 18 years
• All patients who are obese or overweight (\> 25 kg/m2) or non-obese (\< or = 25 kg/m2) operated for abdominal vascular surgery
• Beneficiary or entitled to a social security scheme (except AME)

You may not qualify if:

• Pregnant or breastfeeding woman
• Patient refusal
• Patient deprived of liberty or subject to a legal protection measure (guardianship, curatorship)

Sponsors & Collaborators

• Assistance Publique - Hôpitaux de Paris: lead

Study Sites (1)

Hôpital de la Pitié Salpêtrière

Paris, 75013, France

Location

MeSH Terms

Conditions

COVID-19

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Study Officials

• Olivier BOURRON, Dr

  Hôpital Pitié Salpêtrière - Assistance Publique Hôpitaux de Paris

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Olivier BOURRON, Dr

CONTACT

0142178118; olivier.bourron@aphp.fr

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 28, 2020
• First Posted: November 20, 2020
• Study Start: November 23, 2020
• Primary Completion: November 22, 2021
• Study Completion: November 23, 2021
• Last Updated: November 20, 2020

Record last verified: 2020-10

Locations

FR (1)